Bors, A.; Kozma, A.; Tomán, Á.; Őrfi, Z.; Kondor, N.; Tasnády, S.; Vályi-Nagy, I.; Reményi, P.; Mikala, G.; Andrikovics, H.
IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma. Cancers 2024, 16, 283.
https://doi.org/10.3390/cancers16020283
AMA Style
Bors A, Kozma A, Tomán Á, Őrfi Z, Kondor N, Tasnády S, Vályi-Nagy I, Reményi P, Mikala G, Andrikovics H.
IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma. Cancers. 2024; 16(2):283.
https://doi.org/10.3390/cancers16020283
Chicago/Turabian Style
Bors, András, András Kozma, Ágnes Tomán, Zoltán Őrfi, Nóra Kondor, Szabolcs Tasnády, István Vályi-Nagy, Péter Reményi, Gábor Mikala, and Hajnalka Andrikovics.
2024. "IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma" Cancers 16, no. 2: 283.
https://doi.org/10.3390/cancers16020283
APA Style
Bors, A., Kozma, A., Tomán, Á., Őrfi, Z., Kondor, N., Tasnády, S., Vályi-Nagy, I., Reményi, P., Mikala, G., & Andrikovics, H.
(2024). IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma. Cancers, 16(2), 283.
https://doi.org/10.3390/cancers16020283
